In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Precigen (PGEN – Research Report), with a price target of $10.00. The company’s shares closed last Tuesday at $2.16, close to its 52-week low of $1.91.
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 11.0% and a 39.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Cellectar Biosciences, Harpoon Therapeutics, and Corcept Therapeutics.
Currently, the analyst consensus on Precigen is a Strong Buy with an average price target of $13.33, a 522.9% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $13.00 price target.
Based on Precigen’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $21.56 million and GAAP net loss of $29.76 million. In comparison, last year the company earned revenue of $23.58 million and had a GAAP net loss of $29.51 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. The product pipeline includes Isobutanol, Isobutyraldehyde, Farnesene, and Isoprene. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
Read More on PGEN:
- H.C. Wainwright Thinks Epizyme’s Stock is Going to Recover
- KeyCorp (KEY) Receives a Buy from Wedbush
- Analysts Offer Insights on Technology Companies: Salesforce (CRM) and Jamf Holding (JAMF)
- Analysts Are Bullish on These Healthcare Stocks: ChemoCentryx (CCXI), Taro Pharmaceutical (TARO)
- AbbVie Strengthens Neuroscience Portfolio with Syndesi Acquisition